Hormonal
Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.
While effective, orforglipron often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (12 mg and above). These side effects are the main reason people stop taking the medication. Patients should be aware that higher doses provide more weight loss but also carry a higher risk of stopping treatment due to discomfort. Starting at a lower dose and titrating slowly may help manage these side effects.
gastrointestinal adverse events were significantly more frequent at doses of 12 mg or higher and treatment discontinuation rates were highest at 24 mg (RR:4.61 [95% CI:1.6 to 13.33]) and 36 mg (RR:3.68 [95% CI:2.48 to 5.44]) doses.
Why this rating
Consistent reporting of increased TEAEs and discontinuation across multiple doses in meta-analysis.
Source
Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis
Ravi Kumar Pandey et al. · Endocrinology Diabetes & Metabolism · 2025
DOI 10.1002/edm2.70134
More from this paper
- Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces dose-dependent reductions in body weight (up to 9.8% at 45 mg) and waist circumference, with maximal efficacy observed at higher doses (24-45 mg).Good
- Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →